Kolibri

Market position

Kolibri presents itself as an early-stage European company in cell and gene therapy manufacturing tooling, stating that its technology addresses scalability and cost limitations in current manufacturing processes. It is listed in the Entrepreneurs First portfolio (source 4). The sources contain no third-party market share, ranking or competitive benchmarking data.

Stated differentiators are controlled, low shear stress cell manipulation via tightly regulated acoustic waves; cell-type agnostic operation across therapy modalities; and a scaled-down design in which acoustics concentrate cells into 10x smaller working volumes, plus integration into existing processes without major disruption (source 1).

Technology

The platform uses acoustic waves (acoustophoresis) to manipulate and concentrate cells. According to the company, acoustic waves are tightly regulated to drive media circulation while keeping shear stress minimal, cells are concentrated into working volumes described as 10x smaller to improve cell productivity and cost-effectiveness, and low-shear cell manipulation occurs within a 15-minute cycle. The approach is presented as cell-type agnostic, with gene therapies as the initial focus (sources 0, 1).

Go-to-market

Go-to-market is centered on direct engagement: a partnership/early-access program for selected partners, demo requests, and inbound contact forms segmented into partnership, careers and investment inquiries (sources 1, 2, 3).

Biomanufacturers and organizations producing cell and gene therapies, including those seeking to improve viral vector titers and streamline biomanufacturing processes; the platform is described as cell-type agnostic, applicable across therapy modalities (sources 1, 3).

Geography

Contact and registered addresses are both in Paris, France (Kolibri SAS, 111 Avenue de France, 75013 Paris) (source 3). Entrepreneurs First lists the company under its Paris cohort context (source 4). No other locations are mentioned in the sources.

History

The company announced an initial round of $300,000 with Entrepreneur First and SOSV in 2021, followed by the closing of a €2.8 million seed round in early 2023 led by investors including Creative Ventures, SOSV, Joyance Partners, Fondation CentraleSupélec and BPI France (source 0). An earlier version of the website carries a 2022 copyright notice (source 2), and later pages carry a 2024 notice (sources 0, 1, 3).

Risks & controversies

The company's own funding announcement is internally inconsistent: the headline describes a "$1.6 Million Preseed Round" while the body announces the closing of a €2.8 million seed round, making the disclosed amount ambiguous (source 0). Corporate naming is also inconsistent across the site ("Kolibri SAS" in contact details versus "Kolibri srl" in footers) (sources 0, 1, 3). Performance claims (yield improvement, 10x volume reduction, 15-minute processing) are company-stated and not independently verified in the sources. Note that Kolibri Games (a Berlin mobile games developer owned by Ubisoft) and Colibri Group (a US jewelry supplier) are unrelated companies with similar names and were excluded.